Biocon Shares Drop 5% After Citi Double-Downgrades Stock to ‘Sell’

Biocon Share Price Slips 5% as Citi Issues Double Downgrade and Cuts Target to ₹360

The Biocon share price fell sharply on November 20 after global brokerage firm Citi issued a double downgrade on the stock, moving it from a ‘Buy’ rating directly to ‘Sell’. The downgrade triggered a wave of selling pressure in early trade, pushing the stock down nearly 5 percent to ₹391.30 apiece, marking the second straight session of losses.

This shift in analyst sentiment comes as Biocon continues to face challenges in both its biosimilars and generics businesses. The latest view from Citi indicates heightened concerns around valuations, competitive pressures, and evolving regulatory challenges, which may impact the company’s medium-term growth expectations.

Citi Double-Downgrades Biocon Shares; Cuts Target Price to ₹360

In its latest report, Citi sharply revised its stance, slashing the Biocon target price from ₹430 to ₹360 per share, implying a potential downside of over 12 percent from the stock’s previous closing price of ₹410. The brokerage argued that Biocon’s current valuation appears stretched, especially considering its P/E ratio, which now hovers near 90 — significantly higher than domestic biotech peers.

Citi lowered the valuation multiples assigned to Biocon’s key business segments. It reduced the target multiple of its biosimilars business to 14x EBITDA from the earlier 20x, citing deteriorating market dynamics and shifts in USFDA guidelines that may delay commercialization timelines and intensify competition.

Similarly, the brokerage reduced the multiples for the generics segment to 14x from 16x, factoring in margin pressures and a highly competitive operating environment.

While acknowledging Biocon’s strong global capabilities in biosimilar research and development, Citi warned that pricing pressures and competitive intensity could keep revenue growth below originally anticipated levels.

Also Read : PhysicsWallah Stock Falls 15% as Rs.12,000 Crore Gets Wiped Off Market Cap in Three Days

Biocon Share Price Performance: Recent Gains and Short-Term Weakness

Despite the sudden fall, the Biocon share price has delivered a mixed performance over various time frames. In the past five trading days, the stock has declined nearly 5 percent, reflecting investor reaction to both earnings trends and the latest downgrade.

However, the short-term weakness contrasts with the company’s broader performance:

• Up 9 percent in the past one month

• Up 19 percent over the last six months

This trend signals that while Biocon has seen sustained buying interest over the medium term, the recent analyst downgrade has reintroduced caution among market participants.

Strong Q2 FY26 Earnings Fail to Offset Valuation Concerns

The downgrade comes shortly after Biocon announced a strong set of numbers for the July–September quarter of FY26. The company reported a consolidated net profit of ₹84.5 crore, marking a sharp reversal from the net loss of ₹16 crore recorded in the same quarter last year.

Supported by robust performance in its biosimilars and research services segments, Biocon recorded a 20 percent jump in revenue, rising to ₹4,295.5 crore from ₹3,590.4 crore in Q2 FY25.

At the same time, total expenses grew by 18 percent year-on-year, reaching ₹4,205.3 crore, highlighting cost pressures in manufacturing, raw materials, and regulatory compliance.

Despite the improved financial performance, Citi remains cautious, indicating that “valuation concerns overshadow near-term earnings momentum,” especially amid tightening global guidelines and market-share challenges.

Why Analysts Are Turning Cautious on Biocon

The recent actions by Citi reflect a broader theme impacting the global biosimilars and generics market. Several factors continue to weigh on sentiment around the Biocon share price:

1. Rising Pricing Pressure

Biocon operates in highly competitive markets where pricing continues to be under pressure due to new entrants, payer negotiations, and regulatory requirements for cost-efficient biologics.

2. Regulatory Uncertainties

The USFDA’s updated guidelines for biosimilars have increased approval complexities. Extended review cycles or delayed product launches can impact revenue visibility.

3. High Valuations

With a P/E close to 90, Biocon trades at a significant premium. Analysts argue that the valuation is difficult to justify given current margin pressures.

4. Margin Compression in Generics

Lower margins in the company’s generics division — a major revenue generator — have added to the bearish view from institutional investors.

What Should Investors Watch Next?

For investors tracking the Biocon share price, the next few quarters will be crucial to determining whether Citi’s outlook plays out. Key metrics to monitor include:

• Margin recovery across biosimilars and generics

• Regulatory pipeline milestones and USFDA clearances

• Cost optimization measures

• Expansion in global markets

Biocon’s long-term strengths — including its global biosimilars portfolio and strong execution capabilities — remain intact. However, analysts emphasize that execution risks and rich valuations could limit upside potential in the near term.

Outlook: Should Investors Buy, Sell, or Hold Biocon Shares?

With the Biocon share price reacting sharply to the downgrade, market experts expect continued volatility in the short term. Many analysts advise caution rather than aggressive buying at current levels. Long-term investors may choose to hold positions while keeping track of earnings developments and regulatory updates.

For new entrants, most brokerages suggest waiting for a more attractive entry point or clearer signs of margin stability.

• Nifty 50
• Bank Nifty
• Sensex